The CD200 receptor is a novel and potent regulator of murine and human mast cell function
The CD200 receptor is a novel and potent regulator of murine and human mast cell function
复制标题
DOI：
10.4049/jimmunol.174.3.1348
复制
发表时间：
2005-02-01
影响因子：
4.4
通讯作者：
Phillips, JH
中科院分区：
文献类型：
--
作者：
Cherwinski, HM;Murphy, CA;Phillips, JH
CD 200 R是IG超基因家族的成员，主要在骨髓细胞上表达。最近的体内研究表明，CD 200 R是一种抑制性受体，能够调节炎症免疫反应的激活阈值。在这里，我们提供了明确的证据表明，CD 200 R表达的小鼠和人肥大细胞和CD 200 R的激动剂抗体或配体的参与，在一个有效的抑制肥大细胞脱粒和细胞因子分泌反应。在体外和体内均观察到CD 200 R介导的Fc ε RI活化抑制，并且不需要CD 200 R与Fc ε R1的共连接。与大多数髓系抑制性受体不同，CD 200 R不含磷酸酶募集抑制基序（ITIM）;因此，我们得出结论，CD 200 R代表了一种新的和有效的抑制性受体，可以在体内靶向调节肥大细胞依赖性病理。
CD200R is a member of the Ig supergene family that is primarily expressed on myeloid cells. Recent in vivo studies have suggested that CD200R is an inhibitory receptor capable of regulating the activation threshold of inflammatory immune responses. Here we provide definitive evidence that CD200R is expressed on mouse and human mast cells and that engagement of CD200R by agonist Abs or ligand results in a potent inhibition of mast cell degranulation and cytokine secretion responses. CD200R-mediated inhibition of FcepsilonRI activation was observed both in vitro and in vivo and did not require the coligation of CD200R to FcepsilonR1. Unlike the majority of myeloid inhibitory receptors, CD200R does not contain a phosphatase recruiting inhibitory motif (ITIM); therefore, we conclude that CD200R represents a novel and potent inhibitory receptor that can be targeted in vivo to regulate mast cell-dependent pathologies.